Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clindamycin for the treatment of infections: influence of rifampicin and obesity on PK/PD target attainment
2024-515872-12-00Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of clindamycin and rifampicin in fracture-related infection (FRI), periprosthetic joint infection (PJI), hidradenitis suppurativa (HS) and 1 more (4 cohorts), sponsored by UZ Leuven. Primary endpoint: Pharmacokinetic parameters of clindamycin (and rifampicin where applicable). Planned start Jan 2025; status: authorised.
02
Drugs
clindamycinrifampicin
03
Conditions
fracture-related infection (FRI)periprosthetic joint infection (PJI)hidradenitis suppurativa (HS)bacterial disease
Beyond the preview
Go deeper on 2024-515872-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515872-12-00.